Retension Pharmaceuticals Files S-1 for U.S. IPO
Retension Pharmaceuticals, Inc. filed its Form S-1 registration statement with the SEC on October 8, 2026, initiating its IPO process on NASDAQ or NYSE. The clinical-stage biopharma focuses on neurodegenerative diseases. The filing does not disclose target proceeds or ticker symbol, but marks the formal start of its U.S. listing journey.
51CFO view：S-1 filing demands CFO-level mastery of SEC financial reporting: audited GAAP statements (3 years), SOX 404 internal controls documentation, ASC 718 stock compensation accounting, and MD&A risk quantification. For non-U.S.-trained finance leaders, this is a hard capability threshold—not just process knowledge, but judgment calibrated to SEC expectations.
Retension Pharmaceuticals, Inc. filed its Form S-1 registration statement with the SEC on October 8, 2026, initiating its IPO process on NASDAQ or NYSE. The clinical-stage biopharma focuses on neurodegenerative diseases. The filing does not disclose target proceeds or ticker symbol, but marks the formal start of its U.S. listing journey.
Source：SEC EDGAR · S-1 招股书备案